TKPHF - Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript
Takeda Pharmaceutical Co Ltd (TAK) Q1 2022 Earnings Conference Call July 30, 2021, 06:00 ET Company Participants Christopher O'Reilly - Global Head, IR & Global Finance Christophe Weber - President & CEO Andrew Plump - President, Research & Development Constantine Saroukos - CFO Masato Iwasaki - Representative Director Julie Kim - President, Plasma-Derived Therapies Business Unit Ramona Sequeira - President, US Business Unit & Global Portfolio Commercialization Conference Call Participants Hidemaru Yamaguchi - Citigroup Stacy Ku - Cowen and Company Tatsuyuki Arai - Bank of America Merrill Lynch Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley Fumiyoshi Sakai - Crédit Suisse Kenya Akama - Nikkei Newspaper Seiji Wakao - JPMorgan Chase & Co. Presentation Christopher O'Reilly Thank you very much for your participation in the conference call for the financial results for Q1 fiscal year 2021. My name is Christopher O'Reilly, Global Head of Investor Relations. First, I'd
For further details see:
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2022 Results - Earnings Call Transcript